Discover

Latest News & Updates

Stay informed about our active projects and the latest developments in our field.

POP BIO awarded $2.84M Phase II SBIR for seasonal influenza vaccine development

November 26, 2024

POP Biotechnologies Inc. (POP BIO) received a $2.84M Phase II SBIR under award number 1R44AI181479-01, supported by the National Institute of Allergies and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), to pursue the development of a unique vaccine approach against seasonal influenza.

POP BIO announces findings for an Alzheimer’s Disease polyvalent peptide immunotherapy

September 13, 2024

POP Biotechnologies has announced positive results for their pentavalent peptide vaccine targeting Alzheimer’s Disease, published in Brain Behavior and Immunity. The vaccine, utilizing POP BIO’s SNAP™ technology, demonstrated efficacy in mice by targeting multiple epitopes of amyloid-β and tau proteins, showing potential for treating early-stage AD. The vaccine is now advancing toward clinical trials through EuPOP Life Sciences, a joint venture with EuBiologics.

POP BIO and FunPep Announce Collaboration for Antibody-Inducing Peptide Therapy

August 21, 2024

POP Biotechnologies announces the furtherance of research with FunPep. Advanced preclinical testing of antibody-inducing peptides will be carried out.

POP BIO and EuBiologics’ Shingles Vaccine Enters Phase 1 Clinical Trials

POP Biotechnologies announces the commencement of dosing of the shingles vaccine “EuHZV” in collaboration with EuBiologics in a Phase 1 clinical study in Korea

SNAP Platform Enters Phase I Clinical Studies for RSV

EuBiologics co.,Ltd has started Phase 1 testing of EuRSV, a next-generation RSV vaccine. This is now the second vaccine (after EuCorVac-19) to enter human testing based on University at Buffalo and POP Biotechnologies’ SNAP vaccine adjuvant system.

Janssen Vaccines collaboration with POP BIO’s SNAP vaccine platform results published in Nature Communications

POP Biotechnologies (POP BIO), a Buffalo, NY-based biopharmaceutical startup, announces the publication of new data involving a SNAP-based C HIV-1 Env vaccine available

POP BIO and EuBiologics’ EuCorVac-19 COVID-19 vaccine hits target in Phase 3 trial

POP Biotechnologies (POP BIO), a Buffalo, NY-based biopharmaceutical startup, announces top line interim results of a Phase 3 clinical trial of EuCorVac-19

POP Biotechnologies awarded $2M NIH-NCI Phase II STTR in collaboration with Roswell Park

February 1, 2023

POP Biotechnologies awarded $2M NIH-NCI Phase II STTR in collaboration with Roswell Park BUFFALO, N.Y. — POP Biotechnologies Inc. (POP BIO) received a $2M Phase II

POP Biotechnologies’ SNAP Vaccine System Safe and Effective in a Phase II Clinical Trial for COVID-19

November 30, 2022

POP Biotechnologies (POP BIO), a Buffalo, NY based biopharmaceutical startup, announces the approval of the plan for a phase 3 clinical study of EuCorVac-19, a COVID-19 vaccine candidate developed by South Korean partner EuBiologics (KOSDAQ: 206650, CEO, Dr. Baik YoungOk, Mr. Seukkeun Choi) from the Ministry of Food and Drug Safety in South Korea. EuCorVac-19, is a protein-based vaccine consisting of Eubiologics protein antigen, EulMT, in-licensed from Korea Institute of Science and Technology and the spontaneous-nanoliposome antigen particle (SNAP) technology of POP BIO.

POP Biotechnologies’ SNAP Vaccine Platform Enters Large Scale Clinical Trials for COVID-19

November 30, 2022

POP Biotechnologies (POP BIO), a Buffalo, NY based biopharmaceutical startup, announces the approval of the plan for a phase 3 clinical study of EuCorVac-19, a COVID-19 vaccine candidate developed by South Korean partner EuBiologics (KOSDAQ: 206650, CEO, Dr. Baik YoungOk, Mr. Seukkeun Choi) from the Ministry of Food and Drug Safety in South Korea. EuCorVac-19, is a protein-based vaccine consisting of Eubiologics protein antigen, EulMT, in-licensed from Korea Institute of Science and Technology and the spontaneous-nanoliposome antigen particle (SNAP) technology of POP BIO.